BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dimera Release: Academic Researchers Point to the Merits of Progesterone for Women


7/3/2008 12:18:36 PM

Portland, OR, June 25, 2008 – Heart disease is the leading cause of death and a major cause of disability among women in the United States. Diagnosing and effectively treating heart disease is more difficult in women than men. Four prominent scientists, writing in the July issue of Nature Clinical Practice Cardiovascular Medicine, have called upon the medical community to reconsider and fully explore the benefits of progesterone treatment of menopausal women who suffer from cardiac chest pain and sleep disturbances.

Until recently, many women used hormone replacement therapy (HRT) to help reduce their risk of heart disease. But when the outcomes of large randomized clinical trials failed to demonstrate cardiac benefits, women and their physicians abandoned HRT. In fact, current medical practice guidelines advise against HRT for the purpose of reducing cardiovascular (CV) risk in post-menopausal women.

Lead author Dr. Kent Hermsmeyer asserts that, “it is important to remember that the hormone replacement therapy rejected by these landmark studies did not involve use of progesterone; most HRT involves use of a synthetic progestin called medroxyprogesterone acetate, which does not exhibit the heart protective effects offered by progesterone. Rather than simply rejecting all steroid hormone supplement therapies, it is time to consider what is known and what is not known in the research reported to date.”

The investigators correctly predicted that progesterone, a naturally occurring hormone, plays an important role in reducing CV risk in post-menopausal women. They contend that the apparent blanket condemnation of steroid hormones has not sufficiently distinguished between the CV actions of progesterone and the synthetic progestin that was used in HRT.

The article cites the mounting evidence that progesterone improves CV function and proposes how it improves heart health and well being. It also points out that the route of administration is key, and that delivering progesterone in a cream that is applied to the skin is a safe, effective way to help women reduce CV risk, relieve chest pain, and improve the quality of their sleep.

Contact:
Theresa L. Thompson, PhD
Research Director,
Dimera Incorporated
Phone Number: 503-295-2775
Email Address: tlt@dimera.net



Read at BioSpace.com

Dimera
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES